Is there a reason to perform ICSI in the absence of male factor? Lessons from the Latin American Registry of ART.

study questionDoes the use of ICSI offer any outcome advantage over IVF in patients with non-male factor infertility? SUMMARY ANSWER: We did not find any outcome improvement that justifies the routine use of ICSI over IVF in non-male factor ART cycles. WHAT IS ALREADY KNOWN: Since its introduction in Latin America, the use of ICSI has increased substantially, even among patients without male factor infertility. However, it is not clear whether ICSI provides an advantage over IVF in non-male factor infertility. STUDY DESIGN SIZE DURATION: A retrospective cohort study of fresh cycles performed in 155 ART clinics located in 15 Latin American countries between 2012 and 2014. Records were assessed for 49,813 ART cycles (39,564 ICSI and 10,249 IVF) performed in infertile couples who did not have male factor infertility. Student's PARTICIPANTS/MATERIALS SETTING

methodCycles with the diagnosis of male factor and use of cryopreserved semen and with a freeze-all strategy were excluded. MAIN RESULTS AND THE ROLE OF CHANCE: After correcting for age of female partner, number of oocytes inseminated, number of embryos transferred and transfer at blastocyst stage, we found that the use of ICSI was associated with a significant decrease in the odds of delivery compared to IVF (odds ratio 0.88, 95% CI 0.84 to 0.93; LIMITATIONS REASONS FOR CAUTION: An important limitation of this study is the lack of randomization owing to its retrospective nature. This could result in selection bias, i.e. couples with the worst prognosis undergoing ICSI, or patients with a history of fertilization failure in IVF cycles undergoing ICSI. More than one cycle from the same couple may be included in the study. WIDER IMPLICATIONS OF THE

findingsThe lack of an outcome benefit-and, indeed, a reduced likelihood of delivery-following ICSI in non-male factor infertile couples suggests that ICSI may not be the most appropriate clinical approach in these patients. STUDY FUNDING/COMPETING INTERESTS: None.